Piramal Pharma Q4 Results: Drugmaker Swings Into Net Loss As One-Time Cost Weighs, Revenue Flat

Revenue was impacted by inventory destocking, slower early-stage order inflows in first half of fiscal 2026 and softer traction in inhalation anesthesia across ex-US markets.